Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo

International Journal of Dermatology

Volumn 48, Issue 1, 2009, Pages 86-90

  Xu, Ai E ^a   Zhang, Di Min ^a   Wei, Xiao Dong ^a   Huang, Bo ^a   Lu, Liang Jun ^a  

^a Third Hospital of Hangzhou   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; APPLICATION SITE BURNING; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHOTOGRAPHY; PILOT STUDY; SKIN PIGMENTATION; TREATMENT DURATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; EMOLLIENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; VITILIGO; YOUNG ADULT;

EID: 58149293250     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03852.x     Document Type: Article

References (19)

1. Ortonne JP, Babadoran P, Fitzpatrick TB, et al. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick's Dermatology in General Medicine, 6th edn. New York: McGraw-Hill, 2003: 839-846.
2. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
3. Handa S, Pandhi R, Kaur I. Vitiligo: A retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol 2001; 28: 461-466.
4. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-253.
5. Stern RS, Liebman EJ, Vakeva L. Oral psorialen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer: PUVA follow-up study. J Natl Cancer Inst 1998; 90: 1278-1284.
6. Cho S, Kang HC, Hahm JH. Characteristics of vitiligo in Korean children. Pediatr Dermatol 2000; 17: 189-193.
7. Kostovic K, Pasic A. New treatment modalities for vitiligo: Focus on topical immunomodulators. Drugs 2005; 65: 447-459.
8. Coskun B, Saral Y, Turgut D. Topical 0. 05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
9. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A doubleblind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585.
10. Marsland AM, Grimths CE. The macrolide immunosuppressants in Dermatology: Mechanisms of action. Eur J Derm atol 2002; 12: 618-622.
11. Paller AS. Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. J Pediatr 2001; 138: 163-168.
12. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol 2004; 51(5): 760-766.
13. Parsad D, Pandhi R, Dogra S, et al. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004; 50: 63-67.
14. Bartosik J, Wulf HC, Kobayasi T. Melanin and melanosome complexes in long standing stable vitiligo-an ultrastructural study. Eur J Dermatol 1998; 8: 95-97.
15. Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407-416.
16. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
17. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17.
18. Rico MJ, Naylor M, Elmets CA, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer (Abstract). J Eur Acad Dermatol Venereol 2002; 16(Suppl.): 138.
19. Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol 2003; 139: 651-654.